Arteriocyte Inc.

Arteriocyte has proprietary technology for selecting and harvesting combinations of multiple stem cell types that, when injected into the arterial system, generate new blood vessels to revascularize ischemic cardiac tissue. The company is starting out with autologous stem cells from patient's bone marrow. It intends to move quickly into products made from allogeneic cells sourced from umbilical cord blood, thus providing physicians with a standardized, off-the-shelf therapy.